Induction of apoptosis in endothelial cells is considered an attractive strategy to therapeutically interfere with a solid
tumor's blood supply. In the present paper, we constructed cytotoxic conjugates that specifically target angiogenic endothelial cells, thus preventing typical side effects of apoptosis-inducing drugs. For this purpose, we conjugated the potent
antimitotic agent monomethyl-auristatin-E (MMAE) via a lysosomal cleavable linker to
human serum albumin (HSA) and further equipped this
drug-
albumin conjugate with cyclic c(RGDfK)
peptides for multivalent interaction with alphavbeta3-integrin. The RGD-
peptides were conjugated via either an extended poly(
ethylene glycol) linker or a short alkyl linker. The resulting drug-targeting conjugates RGDPEG-MMAE-HSA and RGD-MMAE-HSA demonstrated high binding affinity and specificity for alphavbeta3-integrin expressing human umbilical vein endothelial cells (HUVEC). Both types of conjugates were internalized by endothelial cells and killed the target cells at low nM concentrations. Furthermore, we observed RGD-dependent binding of the conjugates to C26
carcinoma. Upon i.v. administration to C26-tumor bearing mice, both drug-targeting conjugates displayed excellent
tumor homing properties. Our results demonstrate that RGD-modified
albumins are suitable carriers for cell selective intracellular delivery of cytotoxic compounds, and further studies will be conducted to assess the antivascular and
tumor inhibitory potential of RGDPEG-MMAE-HSA and RGD-MMAE-HSA.